Curative Biotechnology Inc (CUBT) Income Statement
CUBT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCUBT revenue and net income
CUBT profit margins
CUBT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CUBT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $11,091 |
| Cost of revenue | $87,843 | $92,213 | $97,515 | $7,955 | $6,744 | $5,301 | $5,301 | $5,301 | $5,301 | $407 |
| Gross profit | −$87,843 | −$92,213 | −$97,515 | −$7,955 | −$6,744 | −$5,301 | −$5,301 | −$5,301 | −$5,301 | $10,684 |
| Research & development | $6,569 | $14,027 | $269,782 | $2.5M | $779,275 | $0 | — | — | — | — |
| Sales, general & admin | — | $2.2M | $1.6M | $1.9M | $4.2M | $4.6M | $150 | $150 | $1,800 | $6,884 |
| Total operating expenses | $1.4M | $2.3M | $1.8M | $4.4M | $5.0M | $4.6M | $5,451 | $5,451 | $7,101 | $10,684 |
| Operating income | −$1.5M | −$2.4M | −$1.9M | −$4.5M | −$5.0M | −$4.6M | −$5,451 | −$5,451 | −$7,101 | −$1,518 |
| Interest expense | $999,955 | $1.1M | $1.4M | $918,487 | $176,672 | $34,516 | $15,882 | $15,882 | $15,882 | $15,882 |
| Income before taxes | −$2.3M | −$3.6M | −$4.0M | −$5.4M | −$5.3M | −$4.7M | $331,953 | −$29,914 | −$22,983 | −$17,400 |
| Income taxes | — | — | −$5 | $1.2M | $176,672 | $34,516 | $15,882 | $15,882 | — | — |
| Net income | −$2.3M | −$3.6M | −$4.0M | −$5.4M | −$5.3M | −$4.7M | $331,953 | −$29,914 | −$22,983 | −$17,400 |
| EBITDA | −$1.4M | −$2.3M | −$2.5M | −$4.4M | −$5.2M | −$4.6M | −$150 | −$8,731 | −$1,800 | $3,800 |
| EPS (diluted) | −$0.32 | $0.00 | $0.00 | −$0.01 | −$0.01 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | 96.3% |
| Operating margin | — | — | — | — | — | — | — | — | — | −13.7% |
| Net margin | — | — | — | — | — | — | — | — | — | −156.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $21,775 | $21,776 | $21,776 | $21,775 | $22,364 | $21,928 | $21,929 | $21,928 | $21,928 | $26,429 | $91,548 | $1,988 |
| Gross profit | −$21,775 | −$21,776 | −$21,776 | −$21,775 | −$22,364 | −$21,928 | −$21,929 | −$21,928 | −$21,928 | −$26,429 | −$91,548 | −$1,988 |
| Research & development | $4,675 | — | $3,694 | — | $1,150 | $1,725 | $1,075 | $3,525 | $3,775 | $5,652 | $9,739 | $18,696 |
| Sales, general & admin | — | — | — | — | — | $258,886 | $649,620 | — | — | $729,535 | $446,069 | — |
| Total operating expenses | $351,241 | $272,101 | $33,197 | $487,285 | $647,535 | $260,610 | $650,695 | $438,651 | $549,288 | $681,393 | $455,808 | $665,187 |
| Operating income | −$373,016 | −$293,877 | −$54,973 | −$509,059 | −$669,899 | −$283,000 | −$673,000 | −$461,000 | −$571,000 | −$736,000 | −$547,000 | −$667,000 |
| Interest expense | $235,891 | $230,886 | $235,979 | $256,906 | $276,714 | $199,595 | $231,232 | $421,486 | $127,037 | $345,188 | $824,656 | $152,952 |
| Income before taxes | −$608,907 | −$370,269 | −$289,603 | −$764,837 | −$710,147 | −$482,000 | −$903,000 | −$882,000 | −$698,000 | −$1.1M | −$2.0M | −$820,000 |
| Income taxes | — | — | — | — | — | — | — | — | $2 | $1 | $2 | $1 |
| Net income | −$608,907 | −$370,269 | −$289,603 | −$764,837 | −$710,147 | −$482,000 | −$903,000 | −$882,000 | −$698,000 | −$899,000 | −$2.0M | −$820,000 |
| EBITDA | −$351,241 | −$272,101 | −$33,197 | −$487,284 | −$647,535 | −$260,000 | −$649,000 | −$439,000 | −$549,000 | −$681,000 | −$1.1M | −$665,000 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CUBT's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CUBT financial results
Curative Biotechnology reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $2.3 million. Diluted earnings per share came to −$0.32.
See the CUBT stock overview for the latest quote and news, or the CUBT chart for price history and technical indicators.
CUBT income statement FAQ
Does Curative Biotechnology have revenue?
Curative Biotechnology reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Curative Biotechnology profitable?
No. Curative Biotechnology reported a net loss of $2.3 million in fiscal 2025.
How much does Curative Biotechnology spend on research and development?
Curative Biotechnology spent $0.0 million on research and development in fiscal 2025.
What are Curative Biotechnology's earnings per share?
Curative Biotechnology earned $-0.32 per diluted share in fiscal 2025, compared with $-0.00 a year earlier.
When does Curative Biotechnology's fiscal year end?
Curative Biotechnology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.